Emergo Therapeutics
Biopharmaceutical company developing host-directed immune-modulating therapies that reduce pathological cytokine release without causing immunosuppression. Programs focus on respiratory and post-infectious syndromes (including long COVID and influenza-like illness), with activities spanning preclinical development, clinical trials, CMC/GMP strategy, regulatory filings, and intellectual property management.
Industries
Nr. of Employees
small (1-50)
Emergo Therapeutics
Durham, North Carolina, United States
Patents
Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10787502-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10501527-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10494420-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10160796-B2
View Details
Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10787502-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10501527-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10494420-B2
View DetailsMast cell stabilizers for treatment of hypercytokinemia and viral infection
US-10160796-B2
View DetailsProducts
Norketotifen (investigational compound)
Oral investigational small molecule developed to limit mast cell–driven cytokine release and reduce symptom duration in influenza-like illness and long COVID without broad immunosuppression.
Services
Company-provided capabilities in drug development and regulatory progression.
products
See product list above.
Work list placeholder cleanup
Primary development programs and internal services focused on immune-modulating small molecule therapeutics.
worklist end
final
Norketotifen (investigational compound)
Oral investigational small molecule developed to limit mast cell–driven cytokine release and reduce symptom duration in influenza-like illness and long COVID without broad immunosuppression.
Services
Company-provided capabilities in drug development and regulatory progression.
products
See product list above.
Work list placeholder cleanup
Primary development programs and internal services focused on immune-modulating small molecule therapeutics.
worklist end
final
Services
Conduct preclinical efficacy studies and IND-enabling work to support clinical entry.
Design and run clinical trials for immune-modulating therapeutics across acute and chronic indications.
Lead investigational compound in clinical development for long COVID and influenza-like illnesses.
Conduct preclinical efficacy studies and IND-enabling work to support clinical entry.
Design and run clinical trials for immune-modulating therapeutics across acute and chronic indications.
Lead investigational compound in clinical development for long COVID and influenza-like illnesses.
Expertise Areas
- Clinical trial management
- Host-directed antiviral development
- Immune modulation therapies
- CMC and GMP compliance
Key Technologies
- Cytokine modulation
- Host-directed therapy strategy
- Preclinical translational models for respiratory pathogens
- Dose-optimization clinical studies
News & Updates
Company incorporated and patents submitted in September 2016.
Pre-IND package submitted to FDA followed by IND submission supporting clinical programs.
Completed Phase 1 safety trial and initiated exploratory trials for influenza-like illness (NKT201/NKT202 timeline).
Completed optimized dosing study increasing efficacy and expanded development into chronic conditions including long COVID.
Multiple US patents issued covering acute conditions; European patents issued for acute indications.
Began program work addressing long COVID.
Company incorporated and patents submitted in September 2016.
Pre-IND package submitted to FDA followed by IND submission supporting clinical programs.
Completed Phase 1 safety trial and initiated exploratory trials for influenza-like illness (NKT201/NKT202 timeline).
Completed optimized dosing study increasing efficacy and expanded development into chronic conditions including long COVID.
Multiple US patents issued covering acute conditions; European patents issued for acute indications.
Began program work addressing long COVID.